Our insights aren't just pulled from textbooks
Individuals considering extended protocols should understand this temporal limitation in the safety database
Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future
Key Companies: Competitive Landscape of the GLP-1 Weight Loss Drug Market Five ecosystem layers define competition in the GLP-1 Weight Loss Drug Market: approved injectable agonist brands, clinical pipeline challengers, biosimilar manufacturers, telehealth delivery platforms, and direct-to-patient manufacturer access programs
Tesamorelin consistently demonstrates stronger and more sustained IGF-1 elevation in research comparisons a direct consequence of its longer half-life and enhanced receptor engagement
